Aptose Biosciences Company Profile (NASDAQ:APTO)

About Aptose Biosciences

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APTO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.08
  • 50 Day Moving Average: $2.40
  • 200 Day Moving Average: $2.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.64
  • P/E Growth: 0.00
  • Market Cap: $26.82M
  • Outstanding Shares: 12,892,000
  • Beta: 1.3
Additional Links:
Companies Related to Aptose Biosciences:

Analyst Ratings

Consensus Ratings for Aptose Biosciences (NASDAQ:APTO) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.75 (561.06% upside)

Analysts' Ratings History for Aptose Biosciences (NASDAQ:APTO)
Show:
DateFirmActionRatingPrice TargetDetails
6/25/2016Royal Bank Of CanadaReiterated RatingOutperform$23.00View Rating Details
6/13/2016Roth CapitalUpgradeNeutral -> Buy$4.00 -> $8.00View Rating Details
6/9/2016Canaccord GenuityReiterated RatingBuy$7.00View Rating Details
6/9/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Aptose Biosciences (NASDAQ:APTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.36)($0.28)ViewN/AView Earnings Details
3/4/2015($0.31)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aptose Biosciences (NASDAQ:APTO)
Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.30)($0.29)($0.30)
Q2 20162($0.32)($0.31)($0.32)
Q3 20162($0.36)($0.24)($0.30)
Q4 20162($0.38)($0.26)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ:APTO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Aptose Biosciences (NASDAQ:APTO)
DateHeadline
stockhouse.com logoAptose Biosciences T.APS (NASDAQ:APTO)
www.stockhouse.com - August 14 at 8:21 AM
reuters.com logoBRIEF-Aptose Biosciences Q2 loss per share C$0.46 - Reuters (NASDAQ:APTO)
www.reuters.com - August 11 at 3:37 PM
globenewswire.com logoAptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference - GlobeNewswire (press release) (NASDAQ:APTO)
globenewswire.com - August 11 at 12:46 PM
News IconAptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference - P&T Community (NASDAQ:APTO)
www.ptcommunity.com - August 9 at 12:20 PM
finance.yahoo.com logoProstate Cancer Pipeline Market 2016 Review Covering 257 Companies - Yahoo Finance (NASDAQ:APTO)
finance.yahoo.com - July 29 at 3:33 PM
ftsenews.co.uk logoAptose Biosciences, Inc. (APTO) Updated Price Targets - FTSE News (NASDAQ:APTO)
www.ftsenews.co.uk - July 29 at 3:33 PM
News IconDetailed examination of the non small cell lung cancer pipeline products, key players involved and enlists all their ... - WhaTech (NASDAQ:APTO)
www.whatech.com - July 28 at 12:15 PM
News IconAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased By 10.89% - Press Telegraph (NASDAQ:APTO)
presstelegraph.com - July 19 at 3:32 PM
fiscalstandard.com logoAptose Biosciences, Inc. (APTO) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:APTO)
www.fiscalstandard.com - July 17 at 3:29 PM
News IconAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased By 13.51% - Consumer Eagle (NASDAQ:APTO)
www.consumereagle.com - July 16 at 3:31 PM
News IconAptose Biosciences Incorporated (NASDAQ:APTO) Sellers Increased By 13.51% Their Shorts - Consumer Eagle (NASDAQ:APTO)
www.consumereagle.com - July 13 at 3:34 PM
News IconCould Aptose Biosciences Inc Change Direction After Today's Huge Decline? - Engelwood Daily (NASDAQ:APTO)
www.engelwooddaily.com - July 8 at 3:33 PM
fiscalstandard.com logoBroker Outlook For Aptose Biosciences, Inc. (APTO) - Fiscal Standard (NASDAQ:APTO)
www.fiscalstandard.com - July 6 at 3:33 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Aptose Biosciences, Inc. (APTO) - Fiscal Standard (NASDAQ:APTO)
www.fiscalstandard.com - July 4 at 3:31 PM
ftsenews.co.uk logoNew Broker Ratings For Aptose Biosciences, Inc. (APTO) - FTSE News (NASDAQ:APTO)
www.ftsenews.co.uk - July 1 at 3:33 PM
fiscalstandard.com logoAptose Biosciences, Inc. (APTO) Current Analyst Ratings - Fiscal Standard (NASDAQ:APTO)
www.fiscalstandard.com - June 29 at 3:31 PM
globenewswire.com logoAptose Biosciences Announces Results of Annual Meeting of Shareholders - GlobeNewswire (press release) (NASDAQ:APTO)
globenewswire.com - June 22 at 8:19 AM
publicnow.com logoAptose Biosciences Announces Results of Annual Meeting of Shareholders (NASDAQ:APTO)
www.publicnow.com - June 21 at 4:19 PM
globenewswire.com logoAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - GlobeNewswire (press release) (NASDAQ:APTO)
globenewswire.com - June 21 at 3:29 PM
streetinsider.com logoForm 6-K Aptose Biosciences Inc. For: Jun 21 - StreetInsider.com (NASDAQ:APTO)
www.streetinsider.com - June 21 at 3:29 PM
nasdaq.com logoAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders - Nasdaq (NASDAQ:APTO)
www.nasdaq.com - June 21 at 8:18 AM
finance.yahoo.com logoAptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders (NASDAQ:APTO)
finance.yahoo.com - June 21 at 8:00 AM
fiscalstandard.com logoAptose Biosciences, Inc. (APTO) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:APTO)
www.fiscalstandard.com - June 19 at 8:17 AM
benzinga.com logoAptose Upgraded To Buy At Roth, Price Target Doubled (NASDAQ:APTO)
www.benzinga.com - June 13 at 3:43 PM
benzinga.com logoAPTO-253 (NASDAQ:APTO)
www.benzinga.com - June 13 at 11:37 AM
benzinga.com logo6 Largest Price Target Changes For Monday (NASDAQ:APTO)
www.benzinga.com - June 13 at 11:37 AM
finance.yahoo.com logoAptose Biosciences upgraded by ROTH Capital (NASDAQ:APTO)
finance.yahoo.com - June 13 at 6:16 AM
News IconAptose, CrystalGenomics ink global option & license pact for non-covalent BTK/ FLT3/AURK inhibitor (NASDAQ:APTO)
www.pharmabiz.com - June 11 at 11:44 AM
globenewswire.com logoAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor - GlobeNewswire (press release) (NASDAQ:APTO)
globenewswire.com - June 8 at 12:00 PM
reuters.com logoBRIEF-Aptose Biosciences, CrystalGenomics sign cancer drug deal - Reuters (NASDAQ:APTO)
www.reuters.com - June 8 at 12:00 PM
publicnow.com logoAptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor (NASDAQ:APTO)
www.publicnow.com - June 8 at 8:18 AM
finance.yahoo.com logo8:15 am Aptose Biosciences and CrystalGenomics announce exclusive global option and license agreement focused on the development of CG026806 (NASDAQ:APTO)
finance.yahoo.com - June 8 at 8:15 AM
News IconAptose Biosciences, Inc. (NASDAQ:APTO) Stock Update & Estimates - Stock Tick Tock (NASDAQ:APTO)
www.stockticktock.com - June 1 at 11:57 AM
News IconBuy, Sell Or Hold Rating For Aptose Biosciences, Inc. (APTO)? - Share Trading News (NASDAQ:APTO)
www.sharetrading.news - June 1 at 11:57 AM
News IconLatest Analyst Ratings For Aptose Biosciences, Inc. (APTO) - Share Trading News (NASDAQ:APTO)
www.sharetrading.news - May 26 at 11:46 AM
finance.yahoo.com logoAptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016 (NASDAQ:APTO)
finance.yahoo.com - March 14 at 8:00 AM
finance.yahoo.com logoAptose to Participate in Upcoming Investor Conferences (NASDAQ:APTO)
finance.yahoo.com - March 3 at 5:00 PM
finance.yahoo.com logoAptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference (NASDAQ:APTO)
finance.yahoo.com - February 18 at 5:00 PM
News IconAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 4.99% After Market Selling - fdanewsalert.com (NASDAQ:APTO)
www.fdanewsalert.com - February 14 at 2:30 PM
News IconAptose Biosciences Incorporated (NASDAQ:APTO) Shorted Shares Increased 21.15% After Market Selling - fdanewsalert.com (NASDAQ:APTO)
www.fdanewsalert.com - February 7 at 2:06 PM
wallstreet.org logoIt Seems Aptose Biosciences Inc Will Go Up. Have Another Big Increase - WallStreet.org (NASDAQ:APTO)
www.wallstreet.org - February 3 at 2:02 PM
investornewswire.com logoSentiment And Earnings Update For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire (NASDAQ:APTO)
www.investornewswire.com - January 27 at 1:20 PM
stocksdaily.net logoWhy Aptose Biosciences, Inc. (NASDAQ:APTO) Stock Is In The Spotlight? - Stocks Daily (NASDAQ:APTO)
www.stocksdaily.net - January 22 at 7:59 PM
cnn.com logoCytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer - CNNMoney (NASDAQ:APTO)
money.cnn.com - January 20 at 12:57 PM
thestreet.com logoCytoDyn Appoints Denis R. Burger, Ph.D., As Chief Science Officer (NASDAQ:APTO)
www.thestreet.com - January 20 at 12:57 PM
investornewswire.com logoAnalysts Issue Earnings Forecast For Aptose Biosciences, Inc. (NASDAQ:APTO) - Investor Newswire (NASDAQ:APTO)
www.investornewswire.com - January 19 at 7:41 PM
finance.yahoo.com logoAptose Biosciences to Present at the 2015 BIO Investor Forum (NASDAQ:APTO)
finance.yahoo.com - October 15 at 5:00 PM
finance.yahoo.com logoNew Strong Buy Stocks for August 10th - Tale of the Tape (NASDAQ:APTO)
finance.yahoo.com - August 10 at 9:30 AM
finance.yahoo.com logoAptose Biosciences announces results of annual and special meeting of shareholders (NASDAQ:APTO)
finance.yahoo.com - June 10 at 5:00 PM
finance.yahoo.com logoAptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia (NASDAQ:APTO)
finance.yahoo.com - June 2 at 2:00 PM

Social

Aptose Biosciences (NASDAQ:APTO) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff